🟢 Tscan Therapeutics is trading 6.47% up today amid biotech rally and improved risk appetite

Tscan Therapeutics is trading 6.47% up at $0.35 as biotechnology and broader markets rally.

• No new company-specific announcement was identified for September 17, 2026.
• The latest major update, on September 2, was a strategic reorganization prioritizing in vivo solid-tumor programs and pausing further ALLOHA-2 enrollment.
• The move appears mainly tied to sector strength and improved risk appetite rather than a fresh corporate catalyst.